The chief representative of the Gates Foundation praises the Shanghai Pharmaceutical Company: Innovation can only have a profound impact only by the need to truly touch the needs of the disadvantaged people

Author:Report Time:2022.08.28

"We have a particularly deep experience that it is important to deal with global challenges such as disease poverty, but only scientific and technological innovation is not enough." On the Global Health and Development Forum of the Pu 2022 Jiang innovation forum today, Bill and Meilin Zheng Zhijie, the director and chief representative of the Da Gates Foundation, mentioned the two Shanghai pharmaceutical companies, and explained that "only innovation really touches the disadvantaged people in need, so that they can also benefit from scientific and technological progress. It is possible to happen in the far -reaching impact. "

Zheng Zhijie said that this year is the 15th anniversary of the establishment of the Beijing Representative Office of Bill and Melinda Gates Foundation. During the 15 years, the representative office has witnessed that China has become an important contribution to promoting the global health and development. "While China’ s investment in scientific research, in response to the health and development challenges it faces, it also strives to ensure that new technologies and new tools can be converted into effective public products to help save hundreds of millions of lives in their country and other countries. And improve their lives. "

In the speech, Zheng Zhijie specifically mentioned two Shanghai pharmaceutical companies to praise them for the realization of global health and fairness.

The first company is Shanghai Dahua Pharmaceutical. The use of subcutaneous buried contraceptive products can help reduce death of pregnant women, accidental pregnancy, abortion, and infant death, and have been rated by the World Health Organization as a long -term contraception method for safe and efficient reversible contraception. However, due to the lack of products that meet quality requirements and low prices, more than 200 million women in developing countries cannot obtain such contraceptive products.

In order to cope with this challenge, the Gates Foundation searched for corporate partners worldwide, and found that the subcutaneous buried contraceptive products independently developed by Shanghai Dahua Pharmaceutical have a significant advantage of efficient use, safe and cheap. As a result, the Gates Foundation provides technical support for Dahua Pharmaceutical to help improve products. In 2017, it obtained a pre -certification from the World Health Organization and became the second similar product in the world to obtain the certification -this means that the product can pass the internationally internationally internationally Organized procurement and distribution channels benefit more women in low -income countries.

In the following five years, this Shanghai enterprise, which is only more than 100 people in Chongming Island, has delivered more than 6 million sets of underpurlagly planted contraceptive products to countries and regions outside China. The distribution avoids more than 5 million accidental pregnancy and more than 8,000 maternal deaths, helping to save $ 250 million in public health medical expenses.

The other is Shanghai Zerun Biotechnology Co., Ltd., which produces a 9 -valent vaccine of cervical cancer.

Cervical cancer is a malignant tumor that threatens the health of women's lives, and seize the health of more than 300,000 women's health every year. China's cervical cancer burden is serious, the incidence and mortality accounted for almost 1/5 of the world, and it has risen year by year.

Vaccination is an economical and effective way to prevent cervical cancer and cervical cancer. However, because the market that has been listed on cervical cancer is expensive and the supply is insufficient, it cannot provide fair protection for all women.

To solve this challenge, the Gates Foundation and its collaborators have begun to find partners in China. Under the collaboration of various parties, the cervical cancer vaccine developed and produced in China successfully passed the pre -examination certification of the World Health Organization in November 2021. In 2019, Shanghai Zerun Biotechnology Co., Ltd. obtained a $ 2.5 million project fund for the Gates Foundation to accelerate the clinical research and industrialization of cervical cancer vaccine. At present, the vaccine is actively applying for pre -certification of the World Health Organization to supply major international organization procurement.

"In the past 15 years, we are constantly thinking that the global health and development challenges are huge. How can we use limited resources to bring the greatest positive impact on people in the poor areas." Zheng Zhijie said to ensure that this kind of rest and communist cooperation should be ensured It is necessary to have a common goal and concept of partners. The Gates Foundation will be confident in building such a cooperative relationship with Chinese partners.

At the forum, the Shanghai Science and Technology Commission and the Gates Foundation jointly announced the establishment of the "Shanghai Global Health and Development Excellence Center". As a new international cooperation platform, the center will integrate the resources of all parties, jointly promote the construction of global innovation networks, and focus on serving global health and sustainable development.

Author: Xu Qimin

Editor in charge: Ren Quan

*Wenhui exclusive manuscript, please indicate the source for reprinting.

- END -